Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification

Affiliations

• ¹ Department of Clinical and Molecular Medicine, Oncology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
• ² Medical Oncology, Policlinico Umberto I, Sapienza University, Rome, Italy.
• ³ Division of Pathology, Policlinico Umberto I, Sapienza University, Rome, Italy.
• ⁴ Department of Clinical and Molecular Medicine, Pathology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
• ⁵ Department of Clinical and Molecular Medicine, Oncology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy. Electronic address: rgiusti@ospedalesantandrea.it.
• ⁶ Department of Clinical and Molecular Medicine, Oncology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy; Medical Oncology, Policlinico Umberto I, Sapienza University, Rome, Italy.